SPDR S&P Biotech Company Profile (NYSEARCA:XBI)

About SPDR S&P Biotech (NYSEARCA:XBI)

SPDR S&P Biotech logoSPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

Industry, Sector and Symbol:
  • Sector: Financials
  • Industry: Exchange Traded Funds
  • Sub-Industry: N/A
  • Symbol: NYSEARCA:XBI
  • CUSIP: N/A
  • Web: https://www.spdrs.com/
Average Prices:
  • 50 Day Moving Avg: $85.47
  • 200 Day Moving Avg: $76.73
  • 52 Week Range: $53.15 - $88.98
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Profitability:
  • Net Margins: 3,150.61%
  • Return on Equity: 40.83%
  • Return on Assets: 32.53%
Misc:
  • Average Volume: 3.45 million shs.
 

Frequently Asked Questions for SPDR S&P Biotech (NYSEARCA:XBI)

What is SPDR S&P Biotech's stock symbol?

SPDR S&P Biotech trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI."

How often does SPDR S&P Biotech pay dividends? What is the dividend yield for SPDR S&P Biotech?

SPDR S&P Biotech announced a quarterly dividend on Friday, September 15th. Stockholders of record on Monday, September 18th will be given a dividend of $0.037 per share on Monday, September 25th. This represents a $0.15 annualized dividend and a dividend yield of 0.17%. The ex-dividend date of this dividend is Friday, September 15th. View SPDR S&P Biotech's Dividend History.

Who are some of SPDR S&P Biotech's key competitors?

Who are SPDR S&P Biotech's key executives?

SPDR S&P Biotech's management team includes the folowing people:

  • James E. Ross, President, Trustee
  • Peter A. Ambrosini, Chief Compliance Officer
  • Michael P. Riley, Vice President
  • Gary L. French, Treasurer
  • John W. Clark, Assistant Treasurer
  • Matthew W. Flaherty, Assistant Treasurer
  • Chad C. Hallett, Assistant Treasurer of Street tracks series trust
  • Mary Moran Zeven, Secretary
  • Scott M. Zoltowski, Assistant Secretary
  • Dave Kelly, Independent Trustee

Who owns SPDR S&P Biotech stock?

SPDR S&P Biotech's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Guild Investment Management Inc. (0.00%) and Moloney Securities Asset Management LLC (0.00%). View Institutional Ownership Trends for SPDR S&P Biotech.

Who bought SPDR S&P Biotech stock? Who is buying SPDR S&P Biotech stock?

SPDR S&P Biotech's stock was purchased by a variety of institutional investors in the last quarter, including Guild Investment Management Inc. and Moloney Securities Asset Management LLC. View Insider Buying and Selling for SPDR S&P Biotech.

How do I buy SPDR S&P Biotech stock?

Shares of SPDR S&P Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SPDR S&P Biotech's stock price today?

One share of SPDR S&P Biotech stock can currently be purchased for approximately $85.62.


MarketBeat Community Rating for SPDR S&P Biotech (NYSEARCA XBI)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  45
MarketBeat's community ratings are surveys of what our community members think about SPDR S&P Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for SPDR S&P Biotech (NYSEARCA:XBI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for SPDR S&P Biotech (NYSEARCA:XBI)
Price Target History for SPDR S&P Biotech (NYSEARCA:XBI)
Analysts' Ratings History for SPDR S&P Biotech (NYSEARCA:XBI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for SPDR S&P Biotech (NYSEARCA:XBI)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for SPDR S&P Biotech (NYSEARCA:XBI)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History by Quarter for SPDR S&P Biotech (NYSEARCA XBI)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/15/2017quarterly$0.040.18%9/15/20179/18/20179/25/2017
6/16/2017quarterly$0.110.62%6/16/20176/20/20176/26/2017
3/17/2017quarterly$0.020.11%3/17/20173/21/20173/27/2017
12/16/2016quarterly$0.020.12%12/16/201612/20/201612/27/2016
6/19/2015quarterly$0.440.69%6/19/20156/23/20156/29/2015
3/20/2015quarterly$0.250.42%3/20/20153/24/20153/30/2015
12/19/2014quarterly$0.491.03%12/19/201412/23/201412/30/2014
9/19/2014quarterly$0.561.42%9/19/20149/23/20149/29/2014
6/20/2014quarterly$0.621.61%6/20/20146/24/20146/30/2014
3/21/2014quarterly$0.330.87%3/21/20143/25/20143/31/2014
12/20/2013quarterly$0.040.12%12/20/201312/24/201312/31/2013
9/20/2013quarterly$0.090.27%9/20/20139/24/20139/30/2013
3/15/2013quarterly$0.040.18%3/15/20133/19/20133/25/2013
12/21/2012quarterly$0.200.89%12/21/201212/26/20121/4/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for SPDR S&P Biotech (NYSEARCA:XBI)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for SPDR S&P Biotech (NYSEARCA:XBI)
Latest Headlines for SPDR S&P Biotech (NYSEARCA:XBI)
Source:
DateHeadline
prnewswire.com logoClinical Trials and Advanced Development of Innovative Drug Treatments Boosting Biotech Sector Gains - PR Newswire (press release)
www.prnewswire.com - October 18 at 4:37 PM
prnewswire.com logoPositive Developments From Clinical Studies and FDA Approvals Pushing Biotech Stocks to New Highs - PR Newswire (press release)
www.prnewswire.com - October 18 at 4:37 PM
bizjournals.com logoClinical Trials and Advanced Development of Innovative Drug Treatments Boosting Biotech Sector Gains
www.bizjournals.com - October 18 at 10:53 AM
finance.yahoo.com logoPresident Trump reiterates that drug companies 'getting away with murder' but says not much else
finance.yahoo.com - October 17 at 9:15 AM
finance.yahoo.com logoBiotech Fund Flows Turn Negative Ahead of Earnings
finance.yahoo.com - October 14 at 9:32 AM
thestreet.com logoAnalysts Expect XBI Will Reach $108
www.thestreet.com - October 13 at 10:20 AM
barrons.com logo4 Biotech Stocks Primed to Beat - Barron's
www.barrons.com - October 12 at 10:25 AM
seekingalpha.com logoWill Biotech Continue To Boom? - Seeking Alpha
seekingalpha.com - October 12 at 10:25 AM
finance.yahoo.com logoHot Biotech Stocks, ETFs Can Keep Surging
finance.yahoo.com - October 11 at 9:44 AM
finance.yahoo.com logo4 Biotechs to Buy Before Q3 Earnings
finance.yahoo.com - October 10 at 8:32 AM
benzinga.com logoHeaps Of Healthy Health Care ETFs | Benzinga - Benzinga
www.benzinga.com - October 6 at 3:25 PM
finance.yahoo.com logoBullish Biotech Bets After Positive Attention
finance.yahoo.com - October 5 at 6:24 PM
benzinga.com logoSPDR S&P Biotech ETF (ETF:XBI) - Pete Najarian Sees Unusual ... - Benzinga
www.benzinga.com - October 5 at 1:20 PM
finance.yahoo.com logoBulls bet on biotech
finance.yahoo.com - October 4 at 2:35 PM
finance.yahoo.com logoBiotech: Still Undervalued Despite The Rally
finance.yahoo.com - October 3 at 3:31 PM
finance.yahoo.com logoA Good Time to Own Biotech ETFs
finance.yahoo.com - October 3 at 3:31 PM
finance.yahoo.com logoBiotech Can Keep Rallying Through The End Of The Year
finance.yahoo.com - October 3 at 3:31 PM
americanbankingnews.com logoSPDR S&P Biotech Sees Unusually Large Options Volume (XBI)
www.americanbankingnews.com - October 2 at 9:44 AM
msn.com logoTime for Biotech ETFs
www.msn.com - September 30 at 11:53 AM
zacks.com logoForget Hedge Funds: Buy These ETFs Generating Sizable Alpha
www.zacks.com - September 29 at 4:39 PM
seekingalpha.com logoYour Daily Pharma Scoop: Nektar's Potential, Axovant Finally Fails, PTCT AdComm Tomorrow
seekingalpha.com - September 28 at 11:47 AM
nasdaq.com logoXBI, CLVS, EXEL, SRPT: Large Outflows Detected at ETF
www.nasdaq.com - September 28 at 11:47 AM
investopedia.com logoExplaining Biotech's 2017 Resurgence
www.investopedia.com - September 28 at 11:47 AM
finance.yahoo.com logoGene-Editing Could Modify and Cure Disease: CRISPR vs. TALENs
finance.yahoo.com - September 23 at 12:14 PM
investorplace.com logoSPDR S&P Biotech (ETF) (XBI): The Quick Guide to XBI
investorplace.com - September 16 at 8:22 AM
americanbankingnews.com logoSPDR S&P Biotech Plans Quarterly Dividend of $0.04 (XBI)
www.americanbankingnews.com - September 15 at 6:26 PM
thestreet.com logoAnalysts Expect XBI Will Reach $104
www.thestreet.com - September 15 at 11:40 AM
nasdaq.com logoShould You Keep Your Portfolio Healthy with Biotech ETFs? - Nasdaq
www.nasdaq.com - September 13 at 9:28 PM
finance.yahoo.com logoApple Reverses Lower Ahead Of Launch; 2 Dividend Plays To Watch
finance.yahoo.com - September 12 at 12:22 PM
investorplace.com logoThe Move in SPDR S&P Biotech (ETF) (XBI) ETF Is Coming — Get on Board
investorplace.com - September 11 at 2:25 PM
finance.yahoo.com logoWhich Of These Top Tech Plays Gives Access To Nvidia, Bitcoin?
finance.yahoo.com - September 11 at 8:49 AM
finance.yahoo.com logoCheck Out These 2 Hot Biotech Plays Before They're Out Of Range
finance.yahoo.com - September 11 at 8:49 AM
nasdaq.com logoBiotech ETF Investing is Hot, Can Get Hotter - Nasdaq
www.nasdaq.com - September 9 at 10:09 AM
cnbc.com logoThis year's best-performing ETF could rise even higher - CNBC
www.cnbc.com - September 9 at 10:09 AM
investopedia.com logo3 Ways to Trade Strong Performance in Healthcare
www.investopedia.com - September 8 at 10:37 AM
finance.yahoo.com logoThe Summer Of Biotech Isn't Over Yet
finance.yahoo.com - September 7 at 11:30 AM
finance.yahoo.com logoThis year’s best-performing ETF could rise even higher
finance.yahoo.com - September 7 at 11:30 AM
finance.yahoo.com logoWhat Analysts Recommend for Acadia Pharmaceuticals in September
finance.yahoo.com - September 7 at 11:30 AM
finance.yahoo.com logoHealthcare A Bright Spot Amid Cautious Trends
finance.yahoo.com - September 7 at 11:30 AM
finance.yahoo.com logoWhy Biotech Can Keep Adding To Its Gains
finance.yahoo.com - September 7 at 11:30 AM
finance.yahoo.com logo6 ETF Picks for September
finance.yahoo.com - September 5 at 8:27 PM
zacks.com logo6 ETF Picks for Creepy September
www.zacks.com - September 5 at 3:23 PM
finance.yahoo.com logoWhy Biotech Can Add To Its Gains This Month
finance.yahoo.com - September 5 at 3:23 PM
investopedia.com logoWhy The Biotech Rally Has More Room To Run
www.investopedia.com - September 2 at 2:02 AM
finance.yahoo.com logoInvestor Sentiment In Biotech Is More Bullish--With Good Reason
finance.yahoo.com - September 2 at 2:02 AM
finance.yahoo.com logoETF Topper: Biotech Back In Favor
finance.yahoo.com - September 2 at 2:02 AM
nasdaq.com logoBiotech ETFs Remain Bell of the Ball - Nasdaq
www.nasdaq.com - September 1 at 8:58 PM
finance.yahoo.com logoBiotech ETFs Remain Bell of the Ball
finance.yahoo.com - September 1 at 3:56 PM
finance.yahoo.com logoBiotech: What's Not To Like? Well….
finance.yahoo.com - September 1 at 3:56 PM
finance.yahoo.com logoBiotech: The Rally Isn't Over Yet
finance.yahoo.com - September 1 at 11:30 AM

Social

Social activity is not available for this stock.

Chart

SPDR S&P Biotech (XBI) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.